Vivo Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
39
- Investments
-
308
- Portfolio
-
57
- Exits
-
195
Vivo Capital General Information
Company Description
Founded in 1996, Vivo Capital is an investment firm based in Palo Alto, California. The firm seeks to invest globally in biopharmaceuticals, specialty pharmaceuticals, medical devices, and other subsectors of healthcare and life sciences sectors. This firm is a Registered Investment Adviser (RIA).
Business Details
Investor Status
Trade Association
Primary Investor Type
Other Investor Types
Corporate Office
- 192 Lytton Avenue
- Palo Alto, CA 94301
- United States
Vivo Capital Investments (308)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Immunofoco | 18-Apr-2025 | Early Stage VC | Drug Discovery | Clinical Trials - Phase 1 | ||
| Aclaris Therapeutics | 25-Mar-2025 | Drug Discovery | Generating Revenue/Not Profitable | |||
| Surrozen | 24-Mar-2025 | Drug Discovery | Pre-Clinical Trials | |||
| Magnolia Medical Technologies | 15-Jan-2025 | Other Devices and Supplies | Generating Revenue | |||
| TrendTec New Materials | 28-Nov-2024 | Therapeutic Devices | Generating Revenue | |||
| Cidara Therapeutics | 25-Nov-2024 | Biotechnology | Generating Revenue/Not Profitable | |||
| 35Pharma | 22-Nov-2024 | Biotechnology | Clinical Trials - General | |||
| Bright Minds | 04-Nov-2024 | Biotechnology | Generating Revenue | |||
| Agrolend | 18-Oct-2024 | Later Stage VC | Specialized Finance | Generating Revenue | ||
| Tenax Therapeutics | 12-Aug-2024 | PIPE | Biotechnology | Generating Revenue/Not Profitable |
Vivo Capital Exits (195)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Cerebral Therapeutics | 04-Apr-2025 | Out of Business | |
| Tarsus Pharmaceuticals | 13-Mar-2025 | ||
| Ocelot Bio | 20-Dec-2024 | ||
| Bonraybio | 27-Nov-2024 | ||
| Zenas BioPharma | 13-Sep-2024 | ||
| Ribon Therapeutics | 05-Aug-2024 | ||
| Calliditas Therapeutics | 30-Jul-2024 | ||
| ASLAN Pharmaceuticals | 17-Jul-2024 | ||
| Regulus Therapeutics | 09-May-2024 | Public Investment 2nd Offering | |
| Tarsus Pharmaceuticals | 01-Mar-2024 | Public Investment 2nd Offering |
Vivo Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Vivo Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Vivo Capital Co-Investors (229)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| venBio | 9 |
|
|
||
| OrbiMed |
|
|
|||
| Lilly Asia Ventures |
|
|
|||
| Novo Holdings |
|
|
|||
| RA Capital Management |
|
|
Vivo Capital Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Vivo Ventures | Sao Paulo, Brazil | 2022 | |
| Vivo Equity Investment Management | Beijing, China |
Vivo Capital FAQs
-
What is Vivo Capital?
Founded in 1996, Vivo Capital is an investment firm based in Palo Alto, California.
-
When was Vivo Capital founded?
Vivo Capital was founded in 1996.
-
Where is Vivo Capital headquartered?
Vivo Capital is headquartered in Palo Alto, CA.
-
What is Vivo Capital's total asset value?
Vivo Capital has around in total assets under management.
-
How many investments has Vivo Capital made?
Vivo Capital has made 308 investments.
-
What has Vivo Capital invested in?
Vivo Capital has made numerous investments in companies like Immunofoco, Aclaris Therapeutics, and Surrozen within the Drug Discovery industry.
-
What has Vivo Capital invested in recently?
Vivo Capital's latest investment was on 18-Apr-2025 in Immunofoco, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
